Manuel Mohr
Chief Executive Officer D2B3
Seminars
Friday 21st August 2026
Panel Discussion: Diversifying CNS Delivery of Oligos: Nanoparticles, AAV, Peptide Carriers, Physical & Non- Physical BBB Modulation
4:30 pm
- Exploring LNP strategies for CNS delivery, discussing their capacity to encapsulate and protect oligonucleotides, enhance systemic stability, modulate biodistribution, and potentially enable controlled transport across or around the blood–brain barrier
- Advancing peptide-mediated delivery approaches that utilize small targeting or cell-penetrating peptides to facilitate BBB traversal and intracellular uptake, evaluating their modularity, scalability, and potential advantages over antibody-based shuttle platforms
- Evaluating physical BBB modulation techniques, including focused ultrasound and microbubble-assisted disruption, to transiently increase permeability and enable localized brain access, while critically assessing reversibility, safety margins, spatial precision, and translational feasibility
Thursday 20th August 2026
A Novel Biologics Platform for CNS Oligo Delivery: Advancing Safe, Non-Receptor Mediated Brain Targeting
1:30 pm
- Realigning current thinking around the need for CNS-selective delivery strategies beyond receptor targeting
- Explore, non-receptor-mediated biologics platform that enables CNS delivery and discover how preclinical rodent and early non-human primate data support its mechanism and safety profile
- Examine how this approach is being applied within D2B3’s pipeline, and ongoing studies to improve CNS delivery
